Liver Cancer
A Phase III, Randomized, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01/D7029C00001)
- Details
ClinicalTrials.gov ID:
NCT06921785
Diagnosis Type:
NA
USOR Number:
- Address
,
P: